GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vita 34 AG (XTER:V3V) » Definitions » Operating Income

Vita 34 AG (XTER:V3V) Operating Income : €-21.30 Mil (TTM As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Vita 34 AG Operating Income?

Vita 34 AG's Operating Income for the three months ended in Sep. 2023 was €-0.09 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was €-21.30 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Vita 34 AG's Operating Income for the three months ended in Sep. 2023 was €-0.09 Mil. Vita 34 AG's Revenue for the three months ended in Sep. 2023 was €20.41 Mil. Therefore, Vita 34 AG's Operating Margin % for the quarter that ended in Sep. 2023 was -0.44%.

Vita 34 AG's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vita 34 AG's annualized ROC % for the quarter that ended in Sep. 2023 was -0.19%. Vita 34 AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 1.51%.


Vita 34 AG Operating Income Historical Data

The historical data trend for Vita 34 AG's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vita 34 AG Operating Income Chart

Vita 34 AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 2.45 1.97 -2.87 -25.99

Vita 34 AG Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 -18.76 -1.53 -0.92 -0.09

Vita 34 AG Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-21.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vita 34 AG  (XTER:V3V) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vita 34 AG's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-0.356 * ( 1 - 12.99% )/( (175.732 + 157.18)/ 2 )
=-0.3097556/166.456
=-0.19 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vita 34 AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.556/( ( (37.476 + max(-36.69, 0)) + (36.356 + max(-20.18, 0)) )/ 2 )
=0.556/( ( 37.476 + 36.356 )/ 2 )
=0.556/36.916
=1.51 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.771 + 3.394 + 2.234) - (8.798 + 0 + 46.291)
=-36.69

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.009 + 3.317 + 1.522) - (8.112 + 0 + 29.916)
=-20.18

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Vita 34 AG's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.089/20.413
=-0.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vita 34 AG Operating Income Related Terms

Thank you for viewing the detailed overview of Vita 34 AG's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vita 34 AG (XTER:V3V) Business Description

Traded in Other Exchanges
Address
Deutscher Platz 5a, Leipzig, DEU, D-04103
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.
Executives
Jakub Julian Baran Member of the Management Board
Dr. Alexander Granderath Supervisory Board

Vita 34 AG (XTER:V3V) Headlines

No Headlines